BSI has deployed DecisionSite to investigate and analyze several classes of biomarkers, including stratification markers that predict the likelihood of a drug response; efficacy biomarkers that predict a clinical outcome; screening markers for the early detection of diseases; and prognostic markers to predict the likely course of the disease, Spotfire said.
Financial terms of the deal were not disclosed.